Research methods to change clinical practice for patients with rare cancers.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Oncology

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(15)00396-4PMID 26868356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

  2015cited by this paper
• Outcomes and endpoints in cancer trials: bridging the divide.

  2015cited by this paper
• Improving Clinical Trial Efficiency: Thinking outside the Box.

  2015cited by this paper
• Innovative research methods for studying treatments for rare diseases: methodological review

  2014cited by this paper
• Sentinel Lymph Node Biopsy is Associated with Improved Survival in Merkel Cell Carcinoma

  2014cited by this paper
• Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ.

  2014cited by this paper
• New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response

  2014cited by this paper
• Methodology of clinical trials for rare diseases.

  2014cited by this paper
• Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

  2014cited by this paper
• Merkel cell carcinoma, version 1.2014.

  2014cited by this paper
• Clinical Trials in Rare Disease

  2013cited by this paper
• International rare cancers initiative.

  2013cited by this paper
• Genomics-driven oncology: framework for an emerging paradigm.

  2013cited by this paper
• Experimental designs for small randomised clinical trials: an algorithm for choice

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• Rare Cancer Trial Design: Lessons from FDA Approvals

  2012cited by this paper
• Small sample sizes in clinical trials: a statistician's perspective

  2012cited by this paper
• The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.

  2012cited by this paper
• Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

  2012cited by this paper
• Rare cancers are not so rare: the rare cancer burden in Europe.

  2011cited by this paper
• Statistical Issues with the Analysis of Nonrandomized Studies in Comparative Effectiveness Research

  2011cited by this paper
• Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.

  2011cited by this paper
• Outcome--adaptive randomization: is it useful?

  2011cited by this paper
• A framework for applying unfamiliar trial designs in studies of rare diseases.

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• A guide to the design and analysis of small clinical studies

  2011cited by this paper
• Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations.

  2010cited by this paper
• Skin cancers associated with autoimmune conditions among elderly adults

  2010cited by this paper
• Skin cancers associated with HIV infection and solid‐organ transplantation among elderly adults

  2010cited by this paper
• Do rare cancers deserve specific strategies for cancer research?

  2010cited by this paper
• Clinical research for rare disease: opportunities, challenges, and solutions.

  2009cited by this paper
• n‐of‐1 Trials

  2008cited by this paper
• Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.

  2008cited by this paper
• Clinical trials of orphan medicines.

  2008cited by this paper
• Adaptive design methods in clinical trials – a review

  2008cited by this paper
• Can external and subjective information ever be used to reduce the size of randomised controlled trials?

  2008cited by this paper
• Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.

  2007cited by this paper
• Bayesian clinical trials

  2006cited by this paper
• Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer

  2003cited by this paper
• Evaluating non-randomised intervention studies.

  2003cited by this paper
• Strategy for randomised clinical trials in rare cancers

  2003cited by this paper
• Clinical trials and rare diseases.

  2003cited by this paper
• Sample Size

  2003cited by this paper
• The continuing unethical conduct of underpowered clinical trials.

  2002cited by this paper
• The promise and peril of surrogate end points in cancer research

  2002cited by this paper
• Rare diseases and the assessment of intervention: What sorts of clinical trials can we use?

  2001cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• Why we need observational studies to evaluate the effectiveness of health care

  1996cited by this paper
• Clinical trials and rare diseases: a way out of a conundrum

  1995cited by this paper
• Small clinical trials: are they all bad?

  1995cited by this paper

• From Network Governance to Real-World-Time Learning: A High-Reliability Operating Model for Rare Cancers.

  2026cites this paper
• Molecularly redefining small bowel adenocarcinoma to accelerate precision patient care – protocol of a multicenter observational cohort biomarker study

  2025influential citation
• Synthetic control arms and other uses of external data in clinical trials for hematological malignancies.

  2025cites this paper
• Thymic Epithelial Tumors: What’s new and what’s next?

  2025cites this paper
• Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.

  2025cites this paper
• Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment

  2025cites this paper
• MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers

  2024cites this paper
• Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

  2024cites this paper
• Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

  2024cites this paper
• Unraveling Molecular Signatures in Rare Bone Tumors and Navigating the Cancer Pathway Landscapes for Targeted Therapeutics.

  2024cites this paper
• Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

  2023cites this paper
• Challenges and opportunities in rare cancer research in China

  2023cites this paper
• Experimental Models of Sinonasal Tumors for Preclinical Testing of Candidate Targeted Therapies

  2023cites this paper
• Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma

  2023cites this paper
• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  2023cites this paper
• Harnessing Real-World Evidence to Advance Cancer Research

  2023cites this paper
• "Rare cancers": not all together in clinical studies!

  2022cites this paper
• Clinical Practice Guidelines in Cardio-Oncology

  2022cites this paper
• Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis

  2022cites this paper
• Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?

  2022cites this paper
• Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers

  2022cites this paper
• Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders

  2022cites this paper
• Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies.

  2022cites this paper
• Metastatic uveal melanoma: The final frontier.

  2022cites this paper
• Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' views.

  2021cites this paper
• Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations

  2021cites this paper
• Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

  2021cites this paper
• Clinical performance in ERN eUROGEN for penile, testicular, adrenal and soft tissue cancers.

  2021cites this paper
• Meaningful engagement of the patient in rare cancer research: sarcoma as an exemplar.

  2021cites this paper
• Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

  2021cites this paper
• A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.

  2021cites this paper
• Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research

  2021cites this paper
• Networks in Systems Biology: Applications for Disease Modeling

  2020cites this paper
• Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study

  2020cites this paper
• Precision Medicine in Soft Tissue Sarcoma Treatment

  2020cites this paper
• Acute exacerbations in IPF: A clarion call for collaborative research

  2020cites this paper
• Rare Gynecologic Tumors: Coming of Age.

  2020cites this paper
• Sample size estimation for comparing rates of change in K-group repeated binary measurements studies

  2020cites this paper
• Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm.

  2020cites this paper
• Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma.

  2020cites this paper
• Current status and perspectives of patient-derived rare cancer models

  2020cites this paper
• Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma

  2020cites this paper
• The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.

  2020cites this paper
• Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST

  2020cites this paper
• Ex vivo assessment of targeted therapies in a rare metastatic epithelial–myoepithelial carcinoma

  2020cites this paper
• Impact of rarity on Canadian oncology health technology assessment and funding

  2020influential citation
• Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation

  2020cites this paper
• Clinical development of cell therapies for cancer: The regulators' perspective.

  2020cites this paper
• Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction

  2020cites this paper
• Basket trials: From tumour gnostic to tumour agnostic drug development.

  2020cites this paper
• Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases

  2020cites this paper
• Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective

  2020cites this paper
• The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

  2020cites this paper
• Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.

  2020cites this paper
• Challenges for the Optimization of Drug Therapy in the Treatment of Cancer

  2020cites this paper
• The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

  2020cites this paper
• Current status and perspectives of patient-derived rare cancer models

  2020cites this paper
• Innovation in oncology clinical trial design.

  2019cites this paper
• Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation.

  2019cites this paper
• Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

  2019cites this paper
• Precision Oncology—The Quest for Evidence

  2019cites this paper
• The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis☆

  2019cites this paper
• Opportunities and challenges of personalized therapy of patients with HR ALL

  2019cites this paper
• Unmet Needs and Future Outlook of Mesothelioma Management

  2019cites this paper
• Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

  2019cites this paper
• Cancer Clinical Trials Based on Master Protocol

  2019influential citation
• Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study

  2019cites this paper
• Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience.

  2019cites this paper
• New clinical trial designs in the era of precision medicine

  2019cites this paper
• A novel approach to sample size determination of clinical trials for rare diseases assuming symmetry

  2019cites this paper
• Rare Tumours

  2019cites this paper
• Definitions and statistical properties of master protocols for personalized medicine in oncology

  2018cites this paper
• Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

  2018cites this paper
• Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan

  2018cites this paper
• A Bayesian basket trial design using a calibrated Bayesian hierarchical model

  2018cites this paper
• Bayesian interval designs for Phase I trials in rare diseases: application to an innovative therapy in Acute Lymphoblastic Leukemia

  2018cites this paper
• A comprehensive analysis of gestational trophoblastic neoplasia trials posted at online clinical trial registries.

  2018cites this paper
• Real practice studies in oncology: A positive perspective

  2018cites this paper
• Targeted HFpEF therapy based on matchmaking of human and animal models.

  2018cites this paper
• Master protocol trials in oncology: Review and new trial designs

  2018cites this paper
• The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements

  2018cites this paper
• Cost-effectiveness of healthcare interventions for rare cancers: Evidence from a systematic literature review and meta-analysis

  2018cites this paper
• Editor’s foreword: evolving the rare cancer field

  2018cites this paper
• Perspective from the Literature on the Role of Expert Judgment in Scientific and Statistical Research and Practice

  2018cites this paper
• Approche Bayésienne de la survie dans les essais cliniques pour les cancers rares

  2018influential citation
• How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience

  2017cites this paper
• Current status of proteomics of soft tissue sarcomas

  2017cites this paper
• Pediatric Oncology: A Model Of Innovation Through Collaboration

  2017cites this paper
• Advances in the molecular genetics of gliomas — implications for classification and therapy

  2017cites this paper
• Leveraging Genomic Factors to Improve Benefit–Risk

  2017cites this paper
• Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective

  2017cites this paper
• Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

  2017cites this paper
• Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas.

  2017cites this paper
• Trial designs for the development of new drugs

  2017cites this paper
• A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients

  2017cites this paper
• IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities.

  2017cites this paper
• Somatic mutations in salivary duct carcinoma and potential therapeutic targets

  2017cites this paper
• Drug development challenges and strategies to address emerging and resistant fungal pathogens

  2017cites this paper
• Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

  2017cites this paper
• The burden of rare cancers in the United States

  2017cites this paper